KLK2

Creative Biolabs is dedicated to delivering high-quality KLK2 CAR-T products, such as CAR vectors, CAR mRNA, and CAR cells. In addition to our diverse KLK2 CAR-T products, we also provide comprehensive services to assist with the development and optimization of CAR-T therapies. Our comprehensive product portfolio and expert services are designed to facilitate cutting-edge research in the field of CAR-T therapy.

Background

The kallikrein-related peptidase 2 (KLK2) is a member of the kallikrein family of serine proteases. It is primarily expressed in the prostate gland and is associated with the production of semen. KLK2 can cleave the precursor form of prostate-specific antigen (PSA) to generate active PSA. Several studies have shown that altered expression of the KLK2 is associated with various types of cancer, including breast, lung, ovarian, colorectal, and pancreatic cancers. In breast cancer, for example, overexpression of KLK2 has been linked to a more aggressive and metastatic form of the disease.

Fig.1 Schematic of KLK2.¹

Associated Disease

• Prostate cancer
• Breast cancers
• Lung cancer
• Ovarian cancer

Anti-KLK2 CAR-T Services

Anti-KLK2 CAR-T In Vitro Assays

Creative Biolabs offers comprehensive in vitro assays to assess the efficacy and safety of anti-KLK2 CAR-T cell therapy, including:

• Anti-KLK2 CAR-T Expression Test

Successful expression of CAR constructs is crucial for their therapeutic application in CAR T-cell therapy. We provide several methods to evaluate anti-KLK2 CAR expression such as flow cytometry, western blotting, and qPCR. These tests can determine if further optimization or modifications are needed to enhance CAR-mediated immune responses.

• Anti-KLK2 CAR-T Proliferation Test

Creative Biolabs has rich experience in CAR-T cell proliferation tests. To assess anti-KLK2 CAR-T cell proliferation in vitro, cells are cultured in a controlled environment with specific growth factors and nutrients. The cells are stimulated with specific antigens or antigens expressed by cancer cells to trigger their proliferation. The proliferation of CAR-T cells is then evaluated by cell viability test, cell number counting, or by using various techniques such as flow cytometry to track cell division and expansion.

• Anti-KLK2 CAR-T Cytokine Release Test

Creative Biolabs performs cytokine release tests to evaluate the functional activity of CAR-T cells. CAR-T cells are incubated with a specific antigen or target cells in a cytokine release test. The concentration of released cytokines in the culture supernatant is then analyzed using various techniques, including ELISA, flow cytometry-based assays, or multiplex cytokine profiling platforms.

• Anti-KLK2 CAR-T In Vitro Cytotoxicity Assay

CAR-T cytotoxicity tests are essential to assess the effectiveness and safety of CAR-T cell therapy. We provide cytotoxicity tests to help researchers determine the therapeutic potential of CAR-T cells and select the most effective candidates for further development.

Anti-KLK2 CAR-T In Vivo Assays

Creative Biolabs utilizes various techniques to monitor and assess anti-tumor efficacy in animal models, such as bioluminescence imaging, immunohistochemical analysis of tumor tissue sections, flow cytometry analysis of immune cell populations, and cytokine profiling. This allows us to provide valuable information on the efficacy and safety of CAR-T therapies, helping our clients to make informed decisions about the development of their treatments.

Reference

1. Khosroabadi, Ghazaleh, and Saghar Yousefnia. "Mechanistic and Diagnostic Roles of Kallikrein Related Peptidases 2 (KLK2) in Prostate Cancer." Personalized Medicine Journal 8.28 (2023): 5-12.